logo-loader
RNS
viewPhysiomics PLC

Physiomics PLC - Issue of Equity and Director Dealing

RNS Number : 1351V
Physiomics PLC
05 August 2020
 

5 August 2020

Physiomics plc

("Physiomics" or "the Company")

 

Issue of Equity and Director Dealing

 

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that following the receipt of notices of exercise of employee options, 1,655,813 ordinary shares of 0.4p each in the Company ("Ordinary Shares") (the "Options Shares") have now been issued to the following employees at the following exercise prices:

 

Grantee

Number of Options Shares issued

Exercise price per option

Dr J Millen, CEO

1,453,923

2.5p

Other staff

201,890

2.5p

 

Application will be made for the Option Shares to be admitted to trading on AIM, and dealings in the Option Shares are expected to commence on 11 August 2020 ("Admission").  Following Admission, the total number of Ordinary Shares in issue will increase to 97,244,778.

 

For the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules (the "DTRs"), the issued ordinary share capital of the Company following Admission will consist of 97,244,778 Ordinary Shares with voting rights attached (one vote per Ordinary Share).  There are no Ordinary Shares held in treasury.  This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the DTRs.  The Company's share capital additionally comprises 2,481,657,918 deferred shares of 0.036p each which are not quoted and to which no voting rights attach.

 

Following Admission, Dr Millen will be interested in 1,984,279 Ordinary Shares, representing approximately 2.04% of the Company's then issued share capital.

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 



NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Exercise of options over Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Exercise of options over Ordinary share

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.5p

1,453,923

d)

Aggregated information

-     Aggregated volume

-     Price

 

1,453,923

At 2.5p per share

e)

Date of the transaction

5 August 2020

f)

Place of the transaction

Outside of trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCPIMFTMTTMBFM

Quick facts: Physiomics PLC

Price: 6.75

Market: AIM
Market Cap: £6.57 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE